HighPoint Advisor Group LLC Cuts Position in Boston Scientific Corporation $BSX

HighPoint Advisor Group LLC trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 53.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 24,708 shares of the medical equipment provider’s stock after selling 28,735 shares during the period. HighPoint Advisor Group LLC’s holdings in Boston Scientific were worth $2,356,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. Rathbones Group PLC increased its stake in Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC purchased a new position in Boston Scientific in the fourth quarter worth about $1,477,000. Kepler Cheuvreux Suisse SA purchased a new position in Boston Scientific in the third quarter worth about $26,955,000. Finally, Waycross Partners LLC bought a new position in shares of Boston Scientific in the fourth quarter worth approximately $2,384,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several analyst reports. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Truist Financial reduced their target price on Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Finally, Citigroup decreased their target price on Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Trading Up 1.4%

Shares of NYSE:BSX opened at $54.12 on Wednesday. The stock’s 50-day simple moving average is $64.65 and its two-hundred day simple moving average is $82.68. The stock has a market capitalization of $80.43 billion, a price-to-earnings ratio of 22.64, a PEG ratio of 0.98 and a beta of 0.62. Boston Scientific Corporation has a 52-week low of $53.15 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.